Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand

The global radiopharmaceuticals market is projected to grow from USD 8.28 billion in 2026 to USD 15.21 billion by 2035, driven by rising cancer and cardiovascular disease incidence. North America dominates with 43.95% market share, while Asia-Pacific is expected to register the fastest growth. Therapeutic radiopharmaceuticals and Technetium-99m lead their respective segments, with hospitals and clinics as the primary end users.

04/24/2026, 9:57 AM • GlobeNewswire

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Lantheus Holdings reported Q4 2025 revenue of $406.8 million and full-year revenue of $1.54 billion, with adjusted EPS of $1.67 and $6.08 respectively. The company announced a strategic refocus on PET radiodiagnostics and plans to pursue value-maximizing alternatives for radiotherapeutic assets. Despite PYLARIFY sales declining 9.7% in Q4, the company expects up to four FDA approvals in 2026 and provided FY2026 guidance of $1.4-1.45 billion in revenue and $5.00-5.25 adjusted EPS.

02/26/2026, 7:00 AM • GlobeNewswire

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2026: PYLARIFY Exceeds US$ 1 Billion in Net Sales and Became the First Ever Blockbuster Radiodiagnostic

PYLARIFY has become the first blockbuster radiodiagnostic, exceeding $1 billion in 2024 net sales with 24.3% growth. PLUVICTO, a radioligand therapeutic agent, posted $1.392 billion in 2024 sales with 42% growth. PSMA-targeted therapies and radiodiagnostics represent a clinically validated and commercially successful approach for prostate cancer treatment and diagnosis, with multiple radioligands in development.

02/20/2026, 10:55 AM • GlobeNewswire

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

Lantheus Holdings announced it will host an earnings conference call and webcast on February 26, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial and operating results. The company also recently closed the sale of its SPECT business to SHINE Technologies.

02/12/2026, 8:00 AM • GlobeNewswire

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

Lantheus Holdings has completed the sale of its SPECT diagnostic business to SHINE Technologies, a subsidiary of Illuminated Holdings. The transaction includes diagnostic agents like TechneLite, NEUROLITE, and Cardiolite, along with manufacturing facilities in Massachusetts and Canadian operations. Following the divestiture, Lantheus will focus on its PET radiodiagnostics and microbubbles portfolio.

01/02/2026, 8:00 AM • GlobeNewswire

Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year

Nitorum Capital fully exited its stake in Lantheus Holdings, selling 344,444 shares worth $28.2 million in Q3. The exit comes as Lantheus faces significant headwinds including a 77% year-over-year earnings decline, declining sales of its flagship prostate cancer imaging agent, CEO retirement, and margin compression despite strong revenue generation.

12/23/2025, 6:25 PM • The Motley Fool

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential securities misconduct for four companies, alleging false statements, misleading financial reporting, and concealment of material facts that impacted stock prices.

11/13/2025, 5:40 PM • GlobeNewswire

LNTH SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi is investigating potential claims against Lantheus Holdings regarding misleading statements about Pylarify's competitive position, with stock price dropping 28.8% after disappointing Q1 and fiscal year results.

11/09/2025, 8:50 AM • GlobeNewswire

LANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights

A class action lawsuit has been filed against Lantheus Holdings for allegedly making false and misleading statements about Pylarify's competitive position and pricing dynamics between November 2024 and August 2025.

11/08/2025, 10:37 AM • GlobeNewswire

LANTHEUS DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action – LNTH

Rosen Law Firm is notifying Lantheus Holdings investors of a securities class action lawsuit regarding potential misleading statements about Pylarify's competitive position and pricing dynamics during February 26-August 5, 2025.

11/06/2025, 2:50 PM • GlobeNewswire

LNTH DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – LNTH

Rosen Law Firm is notifying Lantheus Holdings investors of a securities class action lawsuit regarding potential misleading statements about Pylarify's competitive position and pricing dynamics during February 26-August 5, 2025.

11/02/2025, 5:27 PM • GlobeNewswire

Deadline Alert: Lantheus Holdings, Inc. (LNTH) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Lantheus Holdings faces a class action lawsuit alleging misleading statements about its Pylarify product's market performance, with stock prices dropping significantly after missing financial estimates in Q1 and Q2 2025.

10/30/2025, 1:44 PM • GlobeNewswire

LNTH INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Law firm announces class action lawsuit against Lantheus Holdings for allegedly making false and misleading statements about Pylarify's competitive position and pricing dynamics during February-August 2025.

10/29/2025, 12:00 PM • GlobeNewswire

LNTH DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LNTH

Rosen Law Firm is investigating potential securities claims for Lantheus Holdings investors who purchased securities between February 26, 2025 and August 5, 2025, alleging misleading statements about Pylarify's competitive position and pricing dynamics.

10/27/2025, 9:37 PM • GlobeNewswire